Anonymous ID: da7452 May 14, 2020, 7:02 p.m. No.9178320   🗄️.is đź”—kun

10x Geonomics, Inc sold by Foresite Capital Mgmt: $116.18m-May 13

 

follow up to a smaller sale in March- Cap#2

 

Class B Common Stock converted to Class A and sold. The shares are owned by James B. Tananbaum and Dana Shonfeld (Trustee at Foresite Capital Management LLC) Tananbaum Family Trust ("Trust").

Jim Tananbaum is the founder and chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm founded in 2011 that has $3 billion in assets under management.

Has worked at 10x Genomics, Amerigroup, and Jazz Pharmaceuticals. co-founded GelTex Pharmaceuticals . GelTex brought two drugs to market. The company was acquired in 1999 for $1.6 billion when its lead drug, Renagel (later renamed Renvela), had an annual revenue run rate exceeding $19.5 million. Decades later, Renvela still has annual sales estimated over $850 million. Jim was the founding chief executive of Theravance, Inc. Under his tenure he raised $400M. Theravance has since split into two parts, one of which is now part of GSK’s respiratory franchise through a joint venture, Innoviva

moar here

https://www.foresitecapital.com/people/jim-tananbaum/

 

10x Genomics, Inc. is a life science technology company. The Company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. The Company’s product consists of chromium single cell gene expression solution, cell immune profiling solution, cell copy number variation (CNV) solution, Cell assay for transposase accessible chromatin (ATAC) solution. The Company’s Chromium platform enables analysis of individual biological components, such as up to millions of single cells. Its Visium platform is designed to identify where biological components are located and how they are arranged with respect to each other. Its molecular assays are used with its Chromium platform, and with its planned Visium platform, to provide sensitive and robust biochemistries that convert minute amounts of biological analytes into detectable signals. Number of employees : 584 people.

https://www.marketscreener.com/10X-GENOMICS-INC-65338646/company/

https://www.finviz.com/insidertrading.ashx?oc=1581219&tc=7&b=2